author-photo

G Hirst

University of California

10

Papers

21

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

Abstract P3-10-06: Expression-based immune signatures as predictors of neoadjuvant targeted-/chemo-therapy response: Experience from the I-SPY 2 TRIAL of ˜1000 patients across 10 therapies

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (4)
Abstract PD6-08: Analysis of immune infiltrates (assessed via multiplex fluorescence immunohistochemistry) and immune gene expression signatures as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 trial

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (4)
Abstract P2-09-08: Analysis of biomarkers for response and resistance to the AKT inhibitor MK-2206 in the neoadjuvant I-SPY 2 trial for stage II-III high-risk breast cancer

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract S2-06: DNA repair deficiency biomarkers and MammaPrint high1/(ultra)high2 risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk breast cancer

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (3)
Abstract P3-06-29: MammaPrint High1/High2 risk class as a biomarker of response to neratinib plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL

2015 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract P3-06-15: Evaluation of HER family protein signaling network as a predictive biomarker for pCR for breast cancer patients treated with neratinib in the I-SPY 2 trial

2015 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract P3-06-25: MammaPrint High1/High2 risk class as a biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL

2015 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract P3-06-05: Evaluation of an in vitro derived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL

2015 Cancer Research
Show All
- Source
- Cite
- Save
Citations (3)